DØ1

NOV 2 3 2005

## BEST AVAILABLE COPY

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1600

GIFFORD, KRASS, GROH, SPRINKLE, ANDERSON & CITKOWSKI, P.C. P.O. Box 7021 Troy, MI 48007-7021

> (248) 647-6000 FACSIMILE (248) 647-5210 info@patlaw.com

jk

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jay M. Meythaler et al.

Attorney Docket: UAB-15402/22

Serial No.:

10/049,328

Group Art Unit: 1614

Filed:

May 15, 2002

Examiner: Donna A. Jagoe

Title:

USE OF GABA AGONISTS FOR TREATMENT OF SPASTIC

DISORDERS, CONVULSIONS, AND EPILEPSY

1.

TO:

Examiner Donna A. Jagoe

FROM:

Avery N. Goldstein

PAGES:

2 (including cover sheet)

**DOCUMENT BEING FAXED:** 

- AMENDMENT UNDER RULE 116;
- 2. ARTICLE "Metabolism of Progabide in Four Animal species and in Man" Ferrandes; and
- 3. STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

#### CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this document for Application Serial Number 10/049,328 is being facsimile transmitted to the Patent and Trademark Office fax number (571)273-8300, Attention

Examiner Donna A. Jagoe, Group 1614, on November 23, 2005.

Janice R. Kuehn

Information contained in this facsimile may be PRIVILEGED and CONFIDENTIAL. It is intended only for the use of the person or entity named above. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is neither intended not permissible. If this facsimile has been received in error, please notify us immediately (call collect) and return the facsimile to us.

RECEIVED **CENTRAL FAX CENTER** 

Serial No. 10/049,328 Response to Office Action of August 24, 2005

NOV 2 3 2005

## BEST AVAILABLE COPY

Attorney Docket No. UAB-15402/22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jay M. Meythaler et al.

Serial No.:

10/049,328

Group Art Unit: 1614

Filing Date: May 15, 2002

Examiner: Donna A. Jagoe

For:

USE OF GABA AGONISTS FOR TREATMENT OF SPASTIC

DISORDERS, CONVULSIONS, AND EPILEPSY

### STATEMENT OF THE SUBSTANCE OF INTERVIEW

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Please enter the following statement of record of interview with regard to the abovereferenced application. Applicant hereby provides the following information with respect to the telephonic interview of November 1, 2005 between Examiner Jagoe and Applicant's representative, Julie Staple. No demonstrations were performed. The interview consisted of a discussion as to the teaching of Aebisher in regard to GABA, including the failure of GABA to cross the blood-brain barrier and the intraventicular delivery of GABA as contra-indicated by the reference. The Bergmann reference was also discussed in that it teaches delivery of progabide. Applicant's representative noted the specification teaching regarding metabolism of progabide, including the formation of a ketone product. Applicant discussed making of record information in this regard.

Pending claims 1-3, 5-13, 15-18, and 26 were discussed in the course of the interview.

1.

# BEST AVAILABLE COPY

Serial No. 10/049,328 Response to Office Action of August 24, 2005

Applicant believes the above summary is in compliance with 37 CFR 1.133. Entry of this summary is hereby requested.

Respectfully submitted,

/Julle Staple/

Julie Staple
Registration No. 50,434
Gifford, Krass, Groh, Sprinkle,
Anderson & Citkowski, P.C.
2701 Troy Center Drive, Suite 330
P.O. Box 7021
Troy, MI 48007-7021
(248) 647-6000

Janice R. Kuchen

Attorney for Applicant

ANG/gs GS-W:\Word Processing\ang\EEC10002-Interview Summary.doc

#### **CERTIFICATE UNDER 37 CFR 1.8(a)**

I hereby certify that this correspondence is being forwarded to the United States Patent

Office via facsimile (571-273-8300) on November 23, 2005.